Tecfidera
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
In May 2006, Biogen acquired Fumapharm and its pipeline multiple sclerosis (MS) drug dimethyl fumarate, coining it first BG-12 and later Tecfidera. Although Tecfidera’s mechanism of action is not yet fully elucidated, it is thought to activate the nuclear factor (erythroid-derived 2)-like 2 transcriptional pathway, which studies have shown defends against oxidative stress-induced neuronal death, protects the blood-brain barrier, and supports maintenance of myelin integrity in the central nervous system. The prevention of immunoactivation of T cells is caused by the combination of cytoprotective and anti-inflammatory properties that Tecfidera displays.
Tecfidera was approved for the treatment of relapsing forms of MS in the US and for the treatment of relapsing-remitting MS in the EU in March 2013 and February 2014, respectively. The drug is also undergoing regulatory review in Japan.
TABLE OF CONTENTS
4 Product Profiles
4 Tecfidera : Multiple sclerosis (MS)
LIST OF FIGURES
8 Figure 42: Datamonitor Healthcare’s drug assessment summary of ozanimod for multiple sclerosis
9 Figure 42: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
12 Figure 42: Ponesimod for multiple sclerosis – SWOT analysis
LIST OF TABLES
5 Table 1: Tecfidera drug profile
6 Table 2: Tecfidera pivotal trial data in multiple sclerosis
10 Table 29: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
13 Table 4: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Lemtrada 
Sign up to the